Esperion Therapeutics (ESPR) Competitors

$3.13 0.00 (0.00%)

Closing price 05/21/2026 04:00 PM Eastern

Extended Trading

$3.14 +0.00 (+0.16%)

As of 05/21/2026 06:46 PM Eastern

ESPR vs. RCUS, ERAS, DNLI, ALMS, and GMTX

Should you buy Esperion Therapeutics stock or one of its competitors? MarketBeat compares Esperion Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Esperion Therapeutics include Arcus Biosciences (RCUS), Erasca (ERAS), Denali Therapeutics (DNLI), Alumis (ALMS), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry.

How does Esperion Therapeutics compare to Arcus Biosciences?

Esperion Therapeutics (NASDAQ:ESPR) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Esperion Therapeutics currently has a consensus target price of $5.54, indicating a potential upside of 77.00%. Arcus Biosciences has a consensus target price of $33.89, indicating a potential upside of 42.27%. Given Esperion Therapeutics' higher probable upside, research analysts clearly believe Esperion Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Esperion Therapeutics has a net margin of 0.12% compared to Arcus Biosciences' net margin of -156.36%. Esperion Therapeutics' return on equity of -0.14% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 1.6% of Esperion Therapeutics shares are held by insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Esperion Therapeutics had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 2 mentions for Esperion Therapeutics and 1 mentions for Arcus Biosciences. Esperion Therapeutics' average media sentiment score of 0.25 beat Arcus Biosciences' score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Esperion Therapeutics has higher revenue and earnings than Arcus Biosciences. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.00	-$22.68M	-$0.06	N/A
Arcus Biosciences	$247M	12.13	-$353M	-$3.18	N/A

Esperion Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

Summary

Esperion Therapeutics beats Arcus Biosciences on 10 of the 16 factors compared between the two stocks.

How does Esperion Therapeutics compare to Erasca?

Esperion Therapeutics (NASDAQ:ESPR) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Esperion Therapeutics has a net margin of 0.12% compared to Erasca's net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Erasca	N/A	-35.31%	-29.49%

In the previous week, Erasca had 11 more articles in the media than Esperion Therapeutics. MarketBeat recorded 13 mentions for Erasca and 2 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 0.25 beat Erasca's score of -0.36 indicating that Esperion Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	0 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 14.2% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Esperion Therapeutics has higher revenue and earnings than Erasca. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.00	-$22.68M	-$0.06	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

Esperion Therapeutics presently has a consensus price target of $5.54, suggesting a potential upside of 77.00%. Erasca has a consensus price target of $18.75, suggesting a potential upside of 61.64%. Given Esperion Therapeutics' higher possible upside, equities analysts plainly believe Esperion Therapeutics is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Esperion Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Erasca has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Summary

Esperion Therapeutics beats Erasca on 9 of the 15 factors compared between the two stocks.

How does Esperion Therapeutics compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Esperion Therapeutics (NASDAQ:ESPR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Esperion Therapeutics has a net margin of 0.12% compared to Denali Therapeutics' net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Esperion Therapeutics	0.12%	-0.14%	0.12%

In the previous week, Denali Therapeutics and Denali Therapeutics both had 2 articles in the media. Denali Therapeutics' average media sentiment score of 1.76 beat Esperion Therapeutics' score of 0.25 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Denali Therapeutics presently has a consensus price target of $35.00, indicating a potential upside of 81.35%. Esperion Therapeutics has a consensus price target of $5.54, indicating a potential upside of 77.00%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Denali Therapeutics is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Denali Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Esperion Therapeutics has higher revenue and earnings than Denali Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.27	-$512.54M	-$2.88	N/A
Esperion Therapeutics	$403.14M	2.00	-$22.68M	-$0.06	N/A

Summary

Denali Therapeutics beats Esperion Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Esperion Therapeutics compare to Alumis?

Esperion Therapeutics (NASDAQ:ESPR) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Esperion Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Alumis has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market.

47.4% of Esperion Therapeutics shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 40.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Esperion Therapeutics has a net margin of 0.12% compared to Alumis' net margin of -2,825.70%. Esperion Therapeutics' return on equity of -0.14% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Alumis	-2,825.70%	-88.79%	-70.72%

Esperion Therapeutics currently has a consensus target price of $5.54, indicating a potential upside of 77.00%. Alumis has a consensus target price of $40.30, indicating a potential upside of 81.78%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Alumis had 18 more articles in the media than Esperion Therapeutics. MarketBeat recorded 20 mentions for Alumis and 2 mentions for Esperion Therapeutics. Alumis' average media sentiment score of 0.29 beat Esperion Therapeutics' score of 0.25 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alumis	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Esperion Therapeutics has higher revenue and earnings than Alumis. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.00	-$22.68M	-$0.06	N/A
Alumis	$24.05M	117.26	-$243.32M	-$1.98	N/A

Summary

Alumis beats Esperion Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Esperion Therapeutics compare to Gemini Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Esperion Therapeutics has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.00	-$22.68M	-$0.06	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Esperion Therapeutics presently has a consensus price target of $5.54, suggesting a potential upside of 77.00%. Given Esperion Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Esperion Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Esperion Therapeutics has a net margin of 0.12% compared to Gemini Therapeutics' net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Gemini Therapeutics	N/A	-38.78%	-35.88%

In the previous week, Esperion Therapeutics had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 2 mentions for Esperion Therapeutics and 0 mentions for Gemini Therapeutics. Esperion Therapeutics' average media sentiment score of 0.25 beat Gemini Therapeutics' score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Esperion Therapeutics	Neutral
Gemini Therapeutics	Neutral

Summary

Esperion Therapeutics beats Gemini Therapeutics on 13 of the 15 factors compared between the two stocks.

Get Esperion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESPR vs. The Competition

Export

Metric	Esperion Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$805.76M	$3.04B	$6.35B	$12.29B
Dividend Yield	N/A	1.96%	2.79%	5.33%
P/E Ratio	-52.17	17.78	21.08	25.34
Price / Sales	2.00	285.45	528.20	79.19
Price / Cash	N/A	57.57	44.13	56.16
Price / Book	-2.61	4.59	10.00	7.01
Net Income	-$22.68M	$74.99M	$3.55B	$335.27M
7 Day Performance	0.32%	0.13%	1.99%	1.28%
1 Month Performance	58.88%	-5.22%	-0.87%	0.16%
1 Year Performance	289.79%	34.78%	36.38%	34.54%

Esperion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESPR Esperion Therapeutics	3.4068 of 5 stars	$3.13 flat	$5.54 +77.0%	+266.9%	$805.76M	$403.14M	N/A	200
RCUS Arcus Biosciences	2.7531 of 5 stars	$24.87 -2.0%	$33.33 +34.1%	+175.9%	$3.19B	$247M	N/A	500
ERAS Erasca	3.4841 of 5 stars	$10.44 +3.2%	$17.88 +71.2%	+850.8%	$3.15B	N/A	N/A	120
DNLI Denali Therapeutics	3.5817 of 5 stars	$19.67 +0.3%	$34.50 +75.4%	+41.0%	$3.11B	$330.53M	N/A	430	Positive News
ALMS Alumis	3.4585 of 5 stars	$23.66 flat	$38.60 +63.1%	+363.8%	$3.01B	$24.05M	N/A	N/A	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESPR) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Esperion Therapeutics (ESPR) Competitors

ESPR vs. RCUS, ERAS, DNLI, ALMS, and GMTX

How does Esperion Therapeutics compare to Arcus Biosciences?

Summary

How does Esperion Therapeutics compare to Erasca?

Summary

How does Esperion Therapeutics compare to Denali Therapeutics?

Summary

How does Esperion Therapeutics compare to Alumis?

Summary

How does Esperion Therapeutics compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR vs. The Competition

Esperion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Esperion Therapeutics (ESPR) Competitors

ESPR vs. RCUS, ERAS, DNLI, ALMS, and GMTX

How does Esperion Therapeutics compare to Arcus Biosciences?

Do analysts recommend ESPR or RCUS?

Is ESPR or RCUS more profitable?

Do institutionals and insiders believe in ESPR or RCUS?

Does the media refer more to ESPR or RCUS?

Which has higher earnings and valuation, ESPR or RCUS?

Which has more volatility & risk, ESPR or RCUS?

Summary

How does Esperion Therapeutics compare to Erasca?

Is ESPR or ERAS more profitable?

Does the media refer more to ESPR or ERAS?

Do institutionals and insiders hold more shares of ESPR or ERAS?

Which has better valuation and earnings, ESPR or ERAS?

Do analysts recommend ESPR or ERAS?

Which has more risk & volatility, ESPR or ERAS?

Summary

How does Esperion Therapeutics compare to Denali Therapeutics?

Is DNLI or ESPR more profitable?

Does the media favor DNLI or ESPR?

Do insiders & institutionals believe in DNLI or ESPR?

Do analysts recommend DNLI or ESPR?

Which has more volatility and risk, DNLI or ESPR?

Which has stronger earnings and valuation, DNLI or ESPR?

Summary

How does Esperion Therapeutics compare to Alumis?

Which has more risk & volatility, ESPR or ALMS?

Do institutionals and insiders believe in ESPR or ALMS?

Is ESPR or ALMS more profitable?

Do analysts prefer ESPR or ALMS?

Does the media favor ESPR or ALMS?

Which has higher valuation and earnings, ESPR or ALMS?

Summary

How does Esperion Therapeutics compare to Gemini Therapeutics?

Which has stronger valuation & earnings, ESPR or GMTX?

Do analysts rate ESPR or GMTX?

Which has more risk & volatility, ESPR or GMTX?

Do institutionals & insiders hold more shares of ESPR or GMTX?

Is ESPR or GMTX more profitable?

Does the media refer more to ESPR or GMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR vs. The Competition

Esperion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools